Collplant Biotechnologies vs Dianthus Therapeutics
Collplant Biotechnologies is the larger business, with $2.4m of revenue in fiscal 2025 against $2.0m for Dianthus Therapeutics (1.2 times as much). Collplant Biotechnologies grew faster (360.4% against -67.3%). Collplant Biotechnologies kept more of each dollar of sales as profit: a net margin of -484.6% against -7973.3%. Collplant Biotechnologies carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Collplant BiotechnologiesCLGN, 2025 | Dianthus TherapeuticsDNTH, 2025 |
|---|---|---|
| Revenue | $2.4m | $2.0m |
| Revenue growth | 360.4% | -67.3% |
| Net income | −$11.5m | −$162m |
| Operating margin | -484.3% | -8739.3% |
| Net margin | -484.6% | -7973.3% |
| Return on equity | -117.6% | -38.4% |
| Free cash flow | −$9.4m | −$129m |
| Cash | $5.6m | $51.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 92 |
| Market value | $54.5m | $4.55bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 66 sales |